Medicine and Dentistry
Head and Neck Cancer
100%
Head and Neck Squamous Cell Carcinoma
72%
Wart Virus
47%
Cetuximab
45%
Malignant Neoplasm
33%
Radiation Therapy
30%
Overall Survival
27%
Phase II Trials
25%
Neoplasm
24%
Epidermal Growth Factor Receptor
23%
Disease
22%
Immunotherapy
21%
Biological Marker
20%
Cisplatin
20%
Neck
19%
Progression Free Survival
19%
Non Small Cell Lung Cancer
18%
Squamous Cell Carcinoma
17%
Human Papillomavirus Type 16
15%
Oropharynx Squamous Cell Carcinoma
14%
Oropharynx
13%
Chemoradiotherapy
12%
Positron Emission Tomography
12%
Gene Mutation
11%
Arm
11%
Clinical Trial
11%
Chemoprophylaxis
10%
Pemetrexed
10%
Salivary Duct Carcinoma
9%
Ipilimumab
9%
Imatinib
9%
Neoadjuvant Chemotherapy
9%
Stereotactic Body Radiation Therapy
9%
Larynx
7%
Recurrent Disease
7%
Xenograft
7%
Platelet Derived Growth Factor Receptor
7%
Hazard Ratio
7%
Base
7%
Motolimod
7%
Re-Irradiation
6%
Thyroid Cancer
6%
Bevacizumab
6%
Intensity Modulated Radiation Therapy
6%
Differentiated Thyroid Cancer
6%
Tongue
6%
Paclitaxel
6%
Phosphotransferase
6%
Toll Like Receptor 8
5%
Adjuvant Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Cancer
85%
Head and Neck Squamous Cell Carcinoma
81%
Cetuximab
52%
Epidermal Growth Factor Receptor
50%
Neoplasm
37%
Squamous Cell Carcinoma
31%
Human Papillomavirus
30%
Progression Free Survival
28%
Biological Marker
27%
Malignant Neoplasm
26%
Erlotinib
26%
Phase II Trials
25%
Overall Survival
24%
Chemotherapy
21%
Disease
21%
Cisplatin
19%
Non Small Cell Lung Cancer
18%
Clinical Trial
16%
Immunotherapy
16%
Placebo
11%
Pemetrexed
10%
Monoclonal Antibody
10%
Adverse Event
9%
Imatinib
9%
Docetaxel
9%
Ficlatuzumab
9%
Phosphatidylinositol 3 Kinase Inhibitor
9%
Everolimus
9%
Recurrent Disease
8%
Chemoradiation Therapy
8%
Carcinogenesis
7%
Dasatinib
7%
Maximum Tolerated Dose
7%
Platelet Derived Growth Factor Receptor
7%
Bevacizumab
6%
Solid Malignant Neoplasm
6%
Mammalian Target of Rapamycin
6%
Non-Steroidal Anti-Inflammatory Drug
6%
Paclitaxel
6%
Monotherapy
6%
Tumor Growth
5%
Diarrhea
5%
Human Papillomavirus Type 16
5%
Disease Specific Survival
5%
Clinical Study
5%
Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
70%
Head-and-neck Cancer
58%
Phase II Trial
25%
High-risk Human Papillomavirus (HR-HPV)
23%
Cetuximab
19%
Overall Survival
16%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
13%
PI3K Inhibitor
9%
Docetaxel
9%
Crosstalk Signal
9%
Phosphatidylinositol 3-kinase Inhibitor
9%
HPV16 E7
9%
HER3
9%
Randomized Phase II Trial
9%
Erlotinib
9%
Sulforaphane
9%
PX-866
9%
Epidermal Growth Factor Receptor
9%
Tumor
8%
Progression-free Survival
8%
Mammalian Target of Rapamycin (mTOR)
8%
Recurrent or Metastatic
8%
Recurrent Metastatic
7%
Non-small Cell Lung Cancer (NSCLC)
7%
Objective Response Rate
7%
Broccoli Extract
7%
Confidence Interval
7%
Clinical Trials
6%
PIK3CA mutation
6%
Chemotherapy
6%
Head-and-neck
6%
Cisplatin
6%
Chemoprevention
5%
EGFR Inhibition
5%
Phase I Study
5%
Clinical Activity
5%
Patient-derived Xenograft
5%
Induction Chemotherapy
5%
HPV Negative
5%
Cancer Patients
5%
Therapeutic Target
5%
Dasatinib
5%
Phase II Clinical Trial
5%
Tobacco-related
5%
Interleukin-6
5%
